Abstract L-p-bromotetramisole was used to inhibit non-intestinal alkaline phosphatase (of liver or bone origin) (EC 3i1-3-1; ALP) in plasma, and intestinal ALP was measured from the uninhibited activity. A simple procedure for the separation and quantification of bone and non-bone alkaline phosphatase (orthophosphoric-monoester phosphohydrolase (alkaline optimum) EC 3-13-1; ALP) in plasma, using wheat-germ lectin to precipitate the bone fraction, has been described.'2 The non-bone supernatant fraction includes liver and, when present, ALP of intestinal origin. For quantification of the liver fraction, therefore, intestinal ALP must be measured separately and subtracted from the non-bone activity. We used densitometric scanning of ALP separated by cellulose acetate electrophoresis for this purpose.3 This is able to show intestinal ALP of f-globulin mobility, and, after neuraminidase pre-treatment, a more anodal so-called "intestinal-variant" fraction,45 both of which are thought to be of intestinal origin. Electrophoresis is, however, inconvenient, and this detracts from the simplicity of the precipitation procedure.
A simple procedure for the separation and quantification of bone and non-bone alkaline phosphatase (orthophosphoric-monoester phosphohydrolase (alkaline optimum) EC 3-13-1; ALP) in plasma, using wheat-germ lectin to precipitate the bone fraction, has been described. ' 2 The non-bone supernatant fraction includes liver and, when present, ALP of intestinal origin. For quantification of the liver fraction, therefore, intestinal ALP must be measured separately and subtracted from the non-bone activity. We used densitometric scanning of ALP separated by cellulose acetate electrophoresis for this purpose.3 This is able to show intestinal ALP of f-globulin mobility, and, after neuraminidase pre-treatment, a more anodal so-called "intestinal-variant" fraction,45 both of which are thought to be of intestinal origin. Electrophoresis is, however, inconvenient, and this detracts from the simplicity of the precipitation procedure.
We have also used a monoclonal antibody reacting with both intestinal and intestinal variant ALP in an immunocapture assay to quantify intestinal origin ALP. For the inhibitor studies, (L-pbromotetramisole oxalate (Aldrich Chemical Company Ltd, Gillingham, Dorset) was added to the substrate solution at a concentration of 01 mmol/l. ALP activity was determined in the presence and in the absence of inhibitor, and the percentage inhibition determined.
Intestinal origin ALP in plasma was quantified immunologically as described previously5 using monoclonal antibody to human intestinal ALP (a gift from the Imperial Cancer Research Fund Laboratories). For this, the antibody was coated on to microtitre plates and used to extract intestinal origin ALP from plasma by overnight incubation at room temperature. After plate washing ALP substrate was added and intestinal ALP activity measured from the colour development following a further two hours of incubation at 37'C. Intestinal origin ALP activity was calculated from a standard curve using standards of activity 2-20 U/1, prepared by dilution of ALP extracted from human small intestinal mucosa. The standard curve was linear up to at least 20 U/1. Samples with activities above this range were appropriately diluted with saline. Interbatch (n = 19) imprecision was less than 6% at 20 U/1. The detection limit for intestinal origin ALP was 0 5 U/1. Using sera containing high concentrations of bone, liver, and placental ALP, cross reaction of the assay with these fractions was less than 0-2%.
The effect of the inhibitor on intestinal ALP was studied using the ALP from small intestine, which was added to plasma previously heated at 65'C for 15 where T = total ALP activity and B = activity in the presence of L-p-bromotetramisole. Intrabatch (n = 19) imprecision in the presence of inhibitor gave a coefficient of variation (CV) of 7 5% at a mean ALP activity of 23-7 U/1. The interbatch (n = 19) CV was 9-1% at a mean activity of 25 8 U/1. intestinal contribution essential if the activity of the liver fraction is to be individually quantified. In men and non-pregnant women activity remaining after subtracting intestinal origin ALP activity from that of the non-bone fraction may be regarded as exclusively measuring ALP of liver origin, though the non-bone fraction may rarely contain nonprecipitated immunoglobulin-bound ALP (present in less than 0 5% of patient plasmas9) or very low activity (generally less than 1 U/1'0) of placental-type ALP in malignancy.
In mid and late pregnancy placental ALP contributes significantly to the non-bone fraction after lectin precipitation, and because it is also resistant to L-p-bromotetramisole-inhibition, this cannot then be used to quantify the intestinal fraction, though, as shown by Mazda and Gyure," theophylline inhibition of non-placental ALP can be used to quantify the placental contribution.
In conclusion, p-bromotetramisole inhibition provides a convenient procedure for the measurement of intestinal origin ALP in the plasma of non-pregnant women and correlates well with measurement by immunocapture assay. If carried out in parallel with wheatgerm lectin precipitation of bone ALP, subtraction of intestinal origin ALP activity from that of the non-bone ALP in the supernatant can measure the ALP that originates from the liver. 
